Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AMGEN INC.

(AMGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Analyst Recommendations on AMGEN INC.
11/22ANALYST RECOMMENDATIONS : Activision Blizzard, Amgen, Ebay, Vmware, Xcel Energy...
11/22Mizuho Securities Cuts Amgen's Price Target to $194 From $222, Citing 'Potential 2022 H..
MT
11/19BMO Capital Starts Amgen at Market Perform With $228 Price Target
MT
11/03Barclays Adjusts Price Target on Amgen to $228 From $230, Maintains Equal-Weight Rating
MT
11/03UBS Lowers Amgen's Price Target to $223 From $246, Maintains Neutral Rating
MT
11/03SVB Leerink Adjusts Price Target on Amgen to $216 From $234, Keeps Market Perform Ratin..
MT
11/01Oppenheimer Adjusts Amgen's Price Target to $272 From $277, Maintains Outperform Rating
MT
10/12AMGEN : Morgan Stanley Adjusts Amgen PT $235 from $251, Keeps Equalweight Rating
MT
09/23AMGEN : Daiwa Securities Downgrades Amgen to Neutral From Outperform, Price Target at $220
MT
09/23ANALYST RECOMMENDATIONS : Amgen, Apple, AstraZeneca, FedEx, T-Mobile US...
09/07AMGEN : Morgan Stanley Downgrades Amgen to Equalweight from Overweight, Adjusts Price Targ..
MT
09/07ANALYST RECOMMENDATIONS : Amgen, Banner, Merck, Oracle, Phoenix...
08/12AMGEN : Mizuho Securities Lifts Amgen's Price Target to $222 From $200, Citing Lumakras Sa..
MT
08/04AMGEN : SVB Leerink Adjusts Amgen's Price Target to $234 from $238, Keeps Market Perform R..
MT
07/16AMGEN : Morgan Stanley Adjusts Price Target on Amgen to $280 From $278, Maintains Overweig..
MT
06/08ANALYST RECOMMENDATIONS : Amgen, Biogen, Halfords, J Sainsbury, Uber...
06/07AMGEN : Oppenheimer Adjusts Amgen's Price Target to $277 from $272, Keeps Outperform Ratin..
MT
06/07AMGEN : SVB Leerink Adjusts Amgen's Price Target to $238 from $230, Keeps Market Perform R..
MT
05/17AMGEN : Oppenheimer Adjusts Amgen PT to $270 From $265, Maintains Outperform Rating
MT
05/03AMGEN : Oppenheimer Adjusts Amgen PT to $265 From $275, Maintains Outperform Rating
MT
04/29AMGEN : UBS Adjusts Amgen's Price Target to $238 From $250, Citing Sotorasib Dosing Questi..
MT
04/28AMGEN : Goldman Sachs Adjusts Amgen's Price Target to $290 From $281, Maintains Buy Rating
MT
04/28AMGEN : Morgan Stanley Adjusts Amgen's Price Target to $278 From $281, Maintains Overweigh..
MT
04/28AMGEN : JPMorgan Adjusts Amgen's Price Target to $215 From $222, Maintains Neutral Rating
MT
04/28AMGEN : Atlantic Equities Downgrades Amgen to Underweight From Neutral, Keeps $200 Price T..
MT
04/28AMGEN : Piper Sandler Adjusts Amgen's Price Target to $255 From $260, Maintains Overweight..
MT
04/28AMGEN : Credit Suisse Raises Amgen's PT to $259 from $265 on Lower-than-Consensus Q1 Reven..
MT
04/28AMGEN : RBC Cuts Price Target on Amgen to $217 From $220, Reiterates Sector Perform Rating
MT
04/28AMGEN INC : Goldman Sachs maintains a Buy rating
MD
04/28AMGEN INC : JP Morgan remains Neutral
MD
04/19AMGEN : Morgan Stanley Adjusts Price Target on Amgen to $281 From $279, Maintains Overweig..
MT
04/05AMGEN : Oppenheimer Adjusts Amgen PT to $275 From $266, Maintains Outperform Rating
MT
03/05AMGEN : SVB Leerink Adjusts Price Target on Amgen to $260 From $252, Maintains Market Perf..
MT
03/05AMGEN : Morgan Stanley Adjusts Price Target on Amgen to $279 From $277, Maintains Overweig..
MT
03/05AMGEN : Barclays Adjusts Amgen's Price Target to $230 From $242, Keeps Equal-Weight Rating
MT
03/04AMGEN INC : Gets a Buy rating from Goldman Sachs
MD
03/04AMGEN INC : JP Morgan sticks Neutral
MD
03/01AMGEN : SVB Leerink Adjusts Price Target on Amgen to $252 From $245, Maintains Market Perf..
MT
02/03AMGEN : Goldman Sachs Adjusts Amgen's Price Target to $276 From $281, Maintains Buy Rating
MT
02/03AMGEN : Morgan Stanley Adjusts Price Target on Amgen to $277 From $285, Maintains Overweig..
MT
02/03AMGEN : Credit Suisse Lowers Amgen's Price Target to $265 from $280 on Expectation for Con..
MT
02/03AMGEN : SVB Leerink Adjusts Amgen PT to $245 From $253, Maintains Market Perform Rating
MT
02/03AMGEN : Cantor Fitzgerald Adjusts Amgen's Price Target to $295 From $280, Reiterates Overw..
MT
02/03AMGEN : Piper Sandler Adjusts Amgen's Price Target to $260 From $280, Maintains Overweight..
MT
01/19AMGEN : Morgan Stanley Adjusts Amgen PT to $285 From $276, Maintains Overweight Rating
MT
2020AMGEN : Daiwa Securities Starts Amgen at Buy With $300 Price Target
MT
2020AMGEN : Oppenheimer Adjusts Amgen's Price Target to $266 From $274, Maintains Outperform R..
MT
2020AMGEN INC : RBC remains Neutral
MD
2020AMGEN : Jefferies Adjusts Price Target for Amgen to $265 From $260, Maintains Buy Rating
MT
2020AMGEN : Morgan Stanley Adjusts Amgen PT to $276 From $275, Maintains Overweight Rating
MT
2020AMGEN : Goldman Sachs Downgrades Amgen to Buy From Conviction Buy
MT
2020AMGEN : SVB Leerink Adjusts Amgen's Price Target to $253 From $243, Keeps at Market Perfor..
MT
2020AMGEN : Oppenheimer Adjusts Amgen PT to $274 From $280, Maintains Outperform Rating
MT
2020AMGEN : Oppenheimer Adjusts Amgen PT to $280 From $275, Maintains Outperform Rating
MT
2020AMGEN : Mizuho Securities Adjusts Amgen PT to $200 From $215, Maintains Neutral Rating
MT
2020SPECIAL REPORT : Big Pharma wages stealth war on drug price watchdog
RE
2020Exxon's Departure From Dow Highlights Market's Retreat From Energy Bets
DJ
2020AMGEN INC : JP Morgan gives a Neutral rating
MD
2020Amgen studying Otezla for coronavirus, looking into other treatments
RE
2020Amgen 2020 outlook falls short of Street estimates; shares slump
RE
2020AMGEN INC : JP Morgan reaffirms its Neutral rating
MD
2019Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
2019Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
2019AMGEN INC : RBC sticks Neutral
MD
2019Teva's new migraine drug helps to contain profit fall
RE
2018Amgen posts higher quarterly EPS, Repatha sales fall short
RE
2018Citron's Left reiterates belief AbbVie shares will fall sharply
RE
2018Biotech's Soon-Shiong hiring bankers for Nant cancer drug IPO
RE
2018Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
2017CEOs suggest Trump tax cut may lift investors more than jobs
RE
2017CEOs suggest Trump tax cut may lift investors more than jobs
RE
2017Spanish stocks lag Europe on political worries but fresh M&A helps
RE
2017AMGEN : fourth quarter profit tops Street view, cholesterol news lifts shares
RE
2017Regeneron, Sanofi to appeal US judge's ban on cholesterol drug sales
RE
2016Pfizer to start shipping biosimilar version of J&J's Remicade in November
RE
1  2Next
Upcoming event on AMGEN INC.